Why it matters
Drug developers from clinical to commercial. This group spans defensive demand, consumer behaviour, rates exposure and innovation, so business-model quality matters more than the label.
%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
All Discover themes
Discover
Biotech & Pharma Innovation
Drug developers from clinical to commercial.
Biotech and pharma pair binary clinical risk with genuine, life-changing innovation. This collection spans biotechnology and drug manufacturers — from clinical-stage developers to commercial-scale pharma — ranked by market cap.
What to check next
Compare pricing power, repeat demand, margins, regulatory risk and the sensitivity of each company to interest rates or consumer weakness.
Main risk
A theme can hide very different risk profiles: biotech, insurers, online retail and property all respond to different drivers.
Showing the 40 largest of 1448 — sort or filter to explore the rest.
- RewardRiskYield0.5%
- RewardRiskYield2.0%
- RewardRiskYield2.7%
- RewardRiskYield2.0%
- RewardRiskYield2.1%
- RewardRiskYield2.5%
- RewardRiskYield3.1%
- RewardRiskYield2.1%
- RewardRiskYield2.4%
- RewardRiskYield3.9%
- RewardRiskYield2.3%
- RewardRiskYield6.4%
- RewardRiskYield3.9%
- RewardRisk
- RewardRiskYield1.9%
- RewardRiskYield9.4%
- RewardRiskYield3.7%
- RewardRiskYield3.7%
- RewardRiskYield0.4%
- RewardRiskYield7.4%
- RewardRiskYield2.4%
- RewardRiskYield1.5%
- RewardRiskYield0.0%
- RewardRiskYield3.5%
- RewardRisk
- RewardRisk
- RewardRiskYield0.2%
- RewardRisk
- RewardRisk
- RewardRiskYield2.0%
- RewardRiskYield1.0%
- RewardRiskYield0.3%
- RewardRisk
- RewardRiskYield1.1%
- RewardRiskYield1.3%
- RewardRiskYield2.4%
- RewardRiskYield1.6%
- RewardRisk
- RewardRisk
- RewardRiskYield2.7%
Related collections
Frequently asked questions
What is the Biotech & Pharma Innovation collection?
Drug developers from clinical to commercial. It currently holds 1448 stocks, each rated by Openbook's Reward and Risk scores. Biotech and pharma pair binary clinical risk with genuine, life-changing innovation.
How are Biotech & Pharma Innovation stocks selected?
Constituents are chosen by a rules-based screen over the full UK and US common-stock universe, then ranked by market capitalisation.
How often is the Biotech & Pharma Innovation list updated?
It is rebuilt from live market data, so the constituents and their rankings update as prices and company fundamentals change — there is no fixed, hand-edited list.
How should I use the Reward and Risk ratings?
Openbook's Reward rating combines a stock's growth, momentum, profitability and valuation into a single 0–100 score, and the Risk rating scores financial strength, volatility and size. Use them to compare names within this theme — broadly, a higher Reward alongside a lower Risk is more attractive. They are quantitative research signals, not investment advice.
Openbook Reward and Risk ratings and factor scores are quantitative signals for research, not investment advice. Data may be delayed. Some US-listed names carry partial factor coverage.